ISAL 2019 | Inhibitors of FLT3 flying into 2019: what to expect this year

Mark Levis

Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, gives us an update on what to expect in the coming year for all things FLT3 for acute myeloid leukemia (AML). Dr Levis discusses the ADMIRAL trial of gilteritnib in the relapsed setting (NCT02421939), whose Phase III data are due to be released in May, as well as the QuANTUM-R (NCT02039726) and QuANTUM-First (NCT02668653) trials of quizartinib. Lastly, he mention the MORPHO study of gilteritnib administered as a maintenance therapy post-ASCT (NCT02997202). This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

Share this video